Huntington National Bank Acquires 82 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Huntington National Bank increased its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 6.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,402 shares of the medical instruments supplier’s stock after acquiring an additional 82 shares during the quarter. Huntington National Bank’s holdings in ICU Medical were worth $218,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of ICUI. Harvest Fund Management Co. Ltd purchased a new stake in ICU Medical in the fourth quarter worth about $33,000. Murphy & Mullick Capital Management Corp bought a new position in ICU Medical during the 4th quarter valued at approximately $52,000. Venturi Wealth Management LLC increased its position in ICU Medical by 64.0% during the 4th quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier’s stock valued at $82,000 after buying an additional 206 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in ICU Medical by 166.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 907 shares of the medical instruments supplier’s stock worth $140,000 after acquiring an additional 567 shares in the last quarter. Finally, Coldstream Capital Management Inc. bought a new stake in ICU Medical in the third quarter worth $227,000. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $139.32 on Friday. The business has a 50-day simple moving average of $151.64 and a two-hundred day simple moving average of $162.55. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The firm has a market cap of $3.42 billion, a price-to-earnings ratio of -30.49 and a beta of 0.73. ICU Medical, Inc. has a fifty-two week low of $93.36 and a fifty-two week high of $196.26.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Raymond James set a $97.00 price target on ICU Medical in a research report on Wednesday, March 12th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Friday. Finally, Jefferies Financial Group raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target for the company in a research report on Wednesday, December 11th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $168.67.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.